Eric Moessinger

Eric joined +ND Capital in 2008 and was the first employee of our Silicon Valley office. He is focused on life sciences investments. Eric is currently a board member of Amphivena, Emulate, Icosavax, Serotiny, SQZ Biotech, Visby Medical and a board observer of IonPath and Inscripta. He previously observed on the board of ARMO (acquired by Lilly) and Twist (Nasdaq: TWST). Eric also helped lead +ND Capital’s investments in Orca and Octant.

Before joining +ND Capital, Eric was a consultant at Bain & Company in Zurich and San Francisco. While at Bain, Eric worked on strategy cases in healthcare, industrial goods and telecommunications and on the turn-around of an electrical component manufacturer. In addition, Eric spent eight months in Bain’s Private Equity Group.

Eric has an MSc from the London School of Economics and a BS/BA from the University of Florida.